Scientific publications

Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature. Scientific Publication

Sep 1, 2020 | Magazine: Amyloidosis

Ramón Lecumberri  1 , Isabel Krsnik  2 , Elham Askari  3 , Maialen Sirvent  4 , Marta S González-Pérez  5 , Fernando Escalante  6 , Virginia Pradillo  7 , Luis E Tamariz  1 , Verónica Cánovas  8   9 , Adrián Alegre  10 , Mercedes Gironella  11 , María E González-García  12 , María S Infante  13 , Sunil Lakhwani  14 , Cristina Martínez-Bilbao  15 , Victoria Dourdil  16 , Ángel Ramírez-Payer  17 , José Sarrá  18 , M Teresa Cibeira  8


Abstract

Management of patients with relapsed or refractory (R/R) AL amyloidosis is complex. Some initial reports have shown positive results with daratumumab in heavily pre-treated AL amyloidosis patients.

In this retrospective multicentric study, 38 patients (mean age 64 ± 9 years) with R/R AL amyloidosis treated with daratumumab were included. Cardiac and renal involvement was present in 76 and 74% of patients, and 42% had ≥3 organs involved. Median number of previous lines of therapy was 2 (range 1-8). Overall hematological response was 72%, including 28% complete responses.

The median time to first hematological response was 2 weeks. A high-quality response (≥very good partial response) was obtained in 65% of patients who had never achieved such depth of response previously. Hematological responses were more frequent among patients receiving daratumumab as second-line therapy compared to subsequent therapies (92 vs. 61%).

Cardiac and renal organ response rates were 37 and 59%. At 12 months, overall and progression-free survival were 59% (95%CI: 0.36-0.77) and 52% (95%CI: 0.29-0.70), respectively.

Daratumumab is a safe and effective drug in the treatment of R/R AL amyloidosis and should be considered early in the course of the disease.

CITATION Amyloid. 2020 Sep;27(3):163-167. doi: 10.1080/13506129.2020.1730791. Epub 2020 Feb 28

Our authors